Clever, non-obvious approach for diagnosing #COVID19: analyzing the sound of a cough.

Now instead of a handshake and talking about the weather, we spend the first 5 minutes of every encounter reconciling psychological states, swapping opinions, and philosophizing about #coronavirus implications.

I collaborated with @steveaoki on #NeonFutureIV. We were pushing the limits of our imaginations around what kind of future that we could create for ourselves and those who follow.

RT @vgr: Nice post from @bryan_johnson ... @osfund has been investing in some interesting startups based on a “global biological immune sys…

Together, @numattech, @arzedaco, @ginkgo, @HelixNano, Augmenta, Nanoly, and the dozens of other companies in the OS Fund portfolio are poised to revolutionize the way our planet responds to a biological crisis.

Given that we are biology, on a big ball of biology, floating in space. Our innovation is our defense. We must know ourselves & enemy. SARS-CoV-2 is in many of us, soon in many more of us. It will mutate. It has and will continue to kill. And it will be around for years.

@ArzedaCo can design therapeutics targeting essential SARS-CoV-2 proteins. By leveraging years of work on human proteases, Arzeda can target the virus’ spike proteins and hope to stop cell invasions at their source, by targeting the virus at one of its weakest points.

@Ginkgo has made its industrial capacity and chemistry design expertise available, at its foundries, for anyone needing to accelerate diagnostic, drug or vaccine development. Gingko makes factories which bring the battle to the virus—an essential part of the supply chain.

@HelixNano is designing an unprecedented vaccine to target two sites on the virus’ surface, useful should any one of those sites mutate, as they are expected to do. A two-target vaccine would still work. This means a greater chance of a useful vaccine viable for a longer time.

Augmenta Bioworks is obtaining the antiviral antibody sequences from the blood of those who had COVID-19 but recovered. With this, they are scaling into a therapeutic which could be dosed into patients by fall.